Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines

被引：95

作者：

DiazGranados, Carlos A. ^{[1
]}

Robertson, Corwin A. ^{[1
]}

Talbot, H. Keipp ^{[2
]}

Landolfi, Victoria ^{[1
]}

Dunning, Andrew J. ^{[1
]}

Greenberg, David P. ^{[1
,3
]}

机构：

[1] Sanofi Pasteur, Swiftwater, PA 18370 USA

[2] Vanderbilt Univ, Med Ctr, Nashville, TN 37212 USA

[3] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA

来源：

VACCINE | 2015年 / 33卷 / 38期

关键词：

Influenza vaccines; human; Vaccines; inactivated; Clinical trial; phase III; Aged; 80 and over; COMMUNITY-ACQUIRED PNEUMONIA; SEASONAL INFLUENZA; UNITED-STATES; ELDERLY SUBJECTS; VACCINATION; EFFICACY; METAANALYSIS; INFECTION; RISK; POPULATION;

D O I：

10.1016/j.vaccine.2015.07.006

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: A recent study showed that a high-dose inactivated influenza vaccine (IIV-HD) was 24.2% more efficacious than a standard-dose inactivated influenza vaccine (IIV-SD) in preventing laboratory-confirmed symptomatic influenza in adults >= 65 years. Here we evaluate the effectiveness of IIV-HD compared to IIV-SD in preventing serious illnesses considered potential sequelae or complications of influenza infection. Methods: The original study was a double-blind, randomized, active-controlled, multicenter trial. Participants were adults >= 65 years randomized to receive IIV-HD or IIV-SD, and followed for 6-8 months post-vaccination for the occurrence of influenza and serious adverse events (SAEs). SAEs were events: leading to death or hospitalization (or its prolongation); considered life-threatening or medically important; or resulting in disability. For the present analysis, reported SAEs were classified as possibly related to influenza by three blinded physicians and rates per 1000 participant-seasons were calculated. Relative vaccine effectiveness (rVE) was estimated as (1 - Rate Ratio) x 100. Results: 31,989 participants were enrolled, with 15,991 and 15,998 randomized to receive IIV-HD and IIV-SD, respectively. IIV-HD was significantly more effective than IN-SD in preventing SAEs possibly related to influenza overall (rVE, 17.7%; 95% confidence interval [CI], 6.6-27.4%) and serious pneumonia (rVE, 39.8%; 95% CI, 19,3-55.14 Borderline significance was observed for the efficacy of IIV-HD relative to IIV-SD for the prevention of all-cause hospitalizations (rVE, 6.9%; 95% CI, 0.5-12.8%). Conclusions: Compared to IIV-SD, IIV-HD reduced the risk of SAEs possibly related to influenza. The observed relative effectiveness against serious pneumonia is particularly noteworthy considering the burden of influenza and pneumonia in older adults. (C) 2015 The Authors. Published by Elsevier Ltd.

引用

页码：4988 / 4993

页数：6

共 42 条

[41] Is the pneurnococcal polysaccharide vaccine effective in preventing pneumonia? [J].